Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

Pfizer Announces Medicare Reimbursement for Inflectra (infliximab-dyyb), the First Biosimilar Monoclonal Antibody Available in the United States

Pfizer  |  January 13, 2017

On Jan. 6, Pfizer Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has included payment information for INFLECTRA (infliximab-dyyb), a biosimilar to REMICADE (infliximab), in its January Average Selling Price (ASP) pricing file. This pricing took effect as of January 1, 2017. Additional claims processing information is listed in the MLN Matters…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologics & BiosimilarsCenters for Medicare & Medicaid Services (CMS)InflectraINFLECTRA (infliximab-dyyb)Pfizer Inc.REMICADE (infliximab)

New Test Yields Rapid Infliximab Drug Concentrations

Will Boggs, MD  |  December 22, 2016

NEW YORK (Reuters Health)—A new test provides rapid infliximab drug concentrations that enable immediate dosing adjustments, researchers from Belgium report. “With this rapid test, our biggest wish is to persuade physicians to now perform and use infliximab measurements also in their own daily clinical practice, as many practical and organizational issues that went along with…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologicsdrug developmentinfliximab

Celltrion Accelerates U.S. Launch of Infliximab-dyyb, a Remicade Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  September 21, 2016

After winning the initial patent infringement lawsuit filed by Janssen, Celltrion Inc. is now shipping Inflectra (infliximab-dyyb), a biosimilar of Remicade (infliximab), to the U.S…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:BiosimilarsCelltrion Inc.FDAFood and Drug Administrationinfliximabinfliximab-dyybOpioids

Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

Kimberly Retzlaff  |  September 8, 2016

The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsdrug updateinfliximabprescriptionpricingrheumatologistrheumatology

Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

Michele B. Kaufman, PharmD, BCGP  |  August 11, 2016

Cross Reactions A recent study published online in March in the Annals of the Rheumatic Diseases investigated if the infliximab biosimilar (CT-P13, infliximab-dyyb), which is marketed in Europe as Inflectra and Remsima, can be safely and effectively substituted for infliximab (Remicade).1 Infliximab and its biosimilar are manufactured via the same process. Researchers set out to…

Filed under:Biologics/DMARDsConditionsDrug Updates Tagged with:AntibodiesBiologicsDisease-modifying antirheumatic drugs (DMARDs)drugFDAinfliximabRheumatoid arthritisrheumatologySafetytherapyTreatmentupdate

Rheumatology Coding Corner Answer: Physical Examination with Infliximab Infusion

From the College  |  July 14, 2016

Take the challenge. CPT: 99214-25, 96413, 96415 x 1, J1745 x 35 ICD-10: M07.68, K51.80 Billing Overview It is appropriate to bill for an E/M visit for this day of service along with the infusion procedure. Modifier 25 should be appended to the E/M, indicating that the patient received a significant, separately identifiable E/M service…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodinginfliximabpatient carephysical examPractice Managementrheumatology

Rheumatology Coding Corner Question: Physical Examination with Infliximab Infusion

From the College  |  July 14, 2016

A 12-year-old male established patient with inflammatory bowel disease with associated juvenile spondyloarthropathy returns to the office for a follow-up visit for his infliximab infusion. The patient reports moderate pain in his right hip after walking for extended periods of time or after sports activities. He denies any other joint pain and denies any joint…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodinginfliximabpatient carephysical examPractice Managementrheumatology

Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs

Michele B. Kaufman, PharmD, BCGP  |  July 6, 2016

In a recent study, 100% of patients with rheumatoid arthritis (RA) on infliximab experienced a cross-reaction when switched to its biosimilar (CT-P13, infliximab-dyyb). Plus in a recent study, a treat-to-target strategy proved effective for treating RA with biological disease-modifying anti-rheumatic drugs…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabBiologicsBiosimilarsDisease-modifying antirheumatic drugs (DMARDs)infliximabinfliximab-dyybRheumatoid Arthritis (RA)

Adalimumab & Infliximab Remain in Newborns after Delivery

Michele B. Kaufman, PharmD, BCGP  |  June 15, 2016

A recent study showed that, when administered during pregnancy, infliximab takes longer to clear an infant’s system than adalimumab…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabAnti-TNFinflammatory bowel diseaseinfliximabpregnancy

Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More

Michele B. Kaufman, PharmD, BCGP  |  May 13, 2016

April 5, 2016, marks a revolutionary day in the treatment of autoimmune diseases: The U.S. Food and Drug Administration (FDA) approved an infliximab (Remicade) biosimilar, known as Inflectra (infliximab-dyyb). Infliximab-dyyb, which is administered by intravenous infusion, is the first biosimilar drug approved to treat rheumatic disease in the U.S.1 Infliximab-dyyb has received approval for almost…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:ApprovalsBiologicsBiosimilarsdrugFDAInflectrainfliximabRemicadeResearchrheumatologySafetyZirletta

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences